Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Azenta Inc

Healthcare US AZTA

22.84USD
-1.05(4.40%)

Last update at 2026-06-04T20:00:00Z

Day Range

22.8024.21
LowHigh

52 Week Range

19.8741.73
LowHigh

Fundamentals

  • Previous Close 23.89
  • Market Cap1216.02M
  • Volume1345923
  • P/E Ratio45.52
  • Dividend Yield-%
  • EBITDA37.33M
  • Revenue TTM595.03M
  • Revenue Per Share TTM12.99
  • Gross Profit TTM 265.16M
  • Diluted EPS TTM0.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -7.14300M -19.12500M -30.43300M -9.93600M -48.96900M
Minority interest - - - - -
Net income -55.76300M -164.89700M -14.25700M -11.28600M -28.86900M
Selling general administrative 261.56M 302.74M 316.28M 252.06M 252.10M
Selling and marketing expenses - - - - -
Gross profit 270.28M 254.62M 263.14M 255.58M 243.81M
Reconciled depreciation 61.21M 90.74M 85.58M 53.70M 65.33M
Ebit -7.14300M -19.12500M -44.40500M -4.00300M -46.54700M
Ebitda 54.07M 71.62M 41.18M 49.70M 18.79M
Depreciation and amortization 61.21M 90.74M 85.58M 53.70M 65.33M
Non operating income net other - - - 19.39M -
Operating income -11.26800M -29.98100M -73.12600M -4.00300M -46.54700M
Other operating expenses 605.09M 603.43M 752.17M 579.52M 544.41M
Interest expense - - 0.00000M 4.59M 2.04M
Tax provision -31.60100M -3.15300M -17.55000M 1.35M -20.10000M
Interest income 18.78M 33.18M 43.73M 20.29M 0.63M
Net interest income 18.78M 33.18M 43.73M 15.70M -1.40500M
Extraordinary items - - - - -
Non recurring - - - 0.71M -
Other items - - - - -
Income tax expense -31.60100M 5.24M -17.55000M 1.35M -20.10000M
Total revenue 593.82M 573.45M 665.07M 555.50M 513.70M
Total operating expenses 281.55M 284.60M 350.24M 279.61M 274.51M
Cost of revenue 323.54M 318.83M 401.93M 299.91M 269.89M
Total other income expense net 4.12M 10.86M 12.93M -5.93300M -2.42200M
Discontinued operations - - - 2144.14M 139.62M
Net income from continuing ops 24.46M -164.17000M -12.88300M -11.28600M -28.86900M
Net income applicable to common shares - - - 2132.86M 110.75M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 2059.58M 2100.04M 2885.72M 3716.12M 1819.51M
Intangible assets 101.81M 248.03M 294.30M 178.40M 186.53M
Earning assets - - - - -
Other current assets 103.25M 82.75M 98.75M 640.01M 369.58M
Total liab 330.70M 331.07M 351.22M 352.74M 494.18M
Total stockholder equity 1726.99M 1768.97M 2534.50M 3363.39M 1325.33M
Deferred long term liab - - - 64.56M -
Other current liab 149.87M 115.15M 140.52M 152.14M 128.94M
Common stock 0.59M 0.59M 0.71M 0.89M 0.88M
Capital stock 0.59M - 0.71M 0.89M 0.88M
Retained earnings 1419.96M 1476.84M 1641.01M 1655.36M -470.05100M
Other liab - - - 72.96M 54.34M
Good will 702.39M 691.41M 784.34M 513.62M 469.36M
Other assets - - - 58.26M 202.29M
Cash 279.78M 310.93M 678.91M 658.27M 227.43M
Cash and equivalents - - - - -
Total current liabilities 237.67M 204.84M 210.93M 230.55M 345.09M
Current deferred revenue 32.57M 31.98M 34.61M 39.75M 25.72M
Net debt -168.61000M -252.13700M -618.47400M -609.04700M -132.66200M
Short term debt 7.78M - - - 148.06M
Short long term debt - - - - -
Short long term debt total 111.17M 58.79M 60.44M 49.23M 94.77M
Other stockholder equity 328.65M 305.00M 955.20M 1791.06M 1775.16M
Property plant equipment - - - 154.47M 180.37M
Total current assets 708.34M 832.81M 1418.96M 2459.35M 777.37M
Long term investments 201.59M - 111.34M 352.02M 3.60M
Net tangible assets - - - 2671.36M 669.44M
Short term investments 61.14M 151.16M 338.87M 911.76M 0.08M
Net receivables 189.21M 172.71M 156.53M 163.76M 119.88M
Long term debt - - - - 49.68M
Inventory 74.96M 115.26M 128.20M 85.54M 60.40M
Accounts payable 37.72M 44.43M 35.80M 38.65M 42.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -22.21300M -13.46400M -62.42600M -83.91600M 19.35M
Additional paid in capital - - - - -
Common stock total equity - - - 0.89M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - 1655.36M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 91.12M 60.31M 70.47M 57.09M 241.90M
Deferred long term asset charges - - - - -
Non current assets total 1351.24M 1267.23M 1466.76M 1256.78M 1042.15M
Capital lease obligations 51.24M - 60.44M 49.23M 45.09M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments -56.60400M 224.74M 431.38M -1270.21500M -0.03000M
Change to liabilities - - - 12.67M 27.03M
Total cashflows from investing activities -90.46100M 224.74M - 1465.59M -146.34900M
Net borrowings -0.98500M -0.78300M - -50.11300M -1.99200M
Total cash from financing activities -9.59100M -659.20700M -844.08000M -62.76200M -25.90600M
Change to operating activities - - - 13.22M 41.85M
Net income -55.76300M -164.89700M -14.25700M 2132.86M 110.75M
Change in cash -24.30500M -363.05500M -357.25100M 755.96M -17.19300M
Begin period cash flow 320.99M 684.04M 1041.30M 285.33M 302.53M
End period cash flow 296.69M 320.99M 684.04M 1041.30M 285.33M
Total cash from operating activities 72.18M 49.74M 17.49M -466.04600M 149.86M
Issuance of capital stock 2.77M 3.28M 0.00000M 5.25M 5.81M
Depreciation 61.21M 90.74M 85.58M 53.70M 65.33M
Other cashflows from investing activities 5.35M 1.48M - 2809.24M 0.20M
Dividends paid - 0.00000M 0.00000M 7.49M 29.73M
Change to inventory -2.67100M 15.90M 5.77M -66.62900M -50.44300M
Change to account receivables -24.56100M -12.06700M 33.99M -31.39700M -69.64300M
Sale purchase of stock 0.00000M -661.70300M -838.51400M 5.25M 0.83M
Other cashflows from financing activities -11.37600M -658.42400M -4.98800M -10.40000M -0.82800M
Change to netincome - - - -2580.47400M 24.99M
Capital expenditures 33.86M 37.39M 39.44M 77.44M 52.80M
Change receivables - - - -31.39700M -
Cash flows other operating - - - -467.54000M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 936.78M -
Change in working capital -22.83700M 3.04M -18.26500M -72.13300M -51.21100M
Stock based compensation 20.88M 14.47M 9.38M 10.67M 27.46M
Other non cash items 95.73M 122.28M -16.71200M -2615.60900M 14.80M
Free cash flow 38.32M 12.35M -21.94600M -543.48100M 97.05M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AZTA
Azenta Inc		 -1.05 4.40% 22.84 45.52 29.07 2.04 0.71 1.45 23.10
ISRG
Intuitive Surgical Inc		 11.53 2.83% 418.82 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 201.48 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 4.49 4.57% 102.66 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.95 2.71% 149.56 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Azenta Inc

200 Summit Drive, Burlington, MA, United States, 01803

Key Executives

Name Title Year Born
Dr. Stephen S. Schwartz CEO, Pres & Director 1959
Mr. Lindon G. Robertson Exec. VP & CFO 1962
Mr. Robin Vacha Sr. VP of Global Operations 1976
Mr. Michael Paulo VP and Chief Information & Digital Officer NA
Sara Silverman Head of Investor Relations NA
Mr. Jason W. Joseph Sr. VP, Gen. Counsel & Corp. Sec. 1971
Mr. John E. O'Brien Sr. VP of Corp. Devel. 1970
Ms. Claribel Purcell Sr. VP of Global Sales NA
Ms. Kimberly Crowley Sr. VP & Chief HR Officer 1978
Mr. J. Robert Woodward Sr. VP of Global Quality & Regulatory NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.